The Comparative Study to Determine the Efficacy of 0.05% Tazarotene Gel Versus 0.1% Adapalene Gel in Patients of Facial Acne Vulgaris
PDF
Cite
Share
Request
Original Article
P: 87-91
September 2022

The Comparative Study to Determine the Efficacy of 0.05% Tazarotene Gel Versus 0.1% Adapalene Gel in Patients of Facial Acne Vulgaris

Turk J Dermatol 2022;16(3):87-91
1. Department of Dermatology, MGM Medical College and Hospital, Aurangabad, Maharashtra, India
No information available.
No information available
Received Date: 23.11.2021
Accepted Date: 11.05.2022
PDF
Cite
Share
Request

ABSTRACT

Introduction:

Acne vulgaris is one of the most common skin disorders that present to Dermatology clinics. The majority of the patients suffer from mild-to-moderate acne, for which topical retinoids form the mainstay of treatment.

Aims and Objectives:

The aim of this article is to study and determine the efficacy and tolerability of 0.05% tazarotene gel against 0.1% adapalene gel in facial acne vulgaris.

Materials and Methods:

Eighty-two facial acne vulgaris patients were randomly divided into two groups. Group A was given 0.05% tazarotene gel, and group B received 0.1% adapalene gel to be applied overnight for a period of 8 weeks. Lesion counting and photographs were recorded every 15 days.

Results:

The mean difference on first follow-up from baseline for tazarotene and adapalene was 6.80 ± 6.42 and 1.48 ± 10.44, and the P-value was 0.013. The final follow-up visit values were 34.77 ± 23.73 and 25.48 ± 13.04, with a P-value of 0.051. The mean percentage change from baseline to last follow-up for tazarotene and adapalene was 60% and 51%, respectively, which were statistically significant for both groups (P < 0.05). More patients in the tazarotene group developed cutaneous side effects such as erythema and burning sensation than those in the adapalene group (P < 0.05).

conclusion:

About 0.05% tazarotene gel has better efficacy than 0.1% adapalene, though associated with more side effects. It can be used as a topical adjunct or as monotherapy in mild-to-moderate facial acne vulgaris.